Cadila Healthcare

Ami Organics IPO: Stock lists tomorrow, grey market premium strong; analysts see up to 35% listing gains

Ami Organics is scheduled to make its stock market debut on Tuesday, 14 September, after receiving over 64 times subscription during IPO.

Ami Organics IPO, Ami Organicsgmp, Ami Organics grey market premium

Reliance Home, India Cements, Bharti Airtel, Cadila, Cipla, Panacea Biotec, Alembic Pharma stocks in focus

Nifty futures were trading 145 points or 0.95 per cent higher at 15,335 on Singaporean Exchange, suggesting a strong opening for BSE Sensex and Nifty 50

stocks in focus, Reliance home, bharti Airtel, cipla, cadila

Technical stocks to buy: Tata Power, UBL show further rally on charts; check Nifty support, resistance levels

Wednesday is an important day for the market and a level based trading approach should be followed. For the Bank-Nifty, 32250 and 32700 should be the trading range

technical stocks, tata power, UBL, nifty

Pharma earnings to reflect full COVID-19 impact in Apr-Jun quarter; 4 pharma stocks to gain up to 16%

Pharmaceutical sector will reflect the full impact of COVID-19 restrictions on the back of pre-buying in chronic therapies in March quarter, underperformance in the acute segment due to delays in elective surgeries and shut-d

Buy on Cadila Healthcare with target of Rs 370

We initiate coverage on Cadila Healthcare (CDH) with BUY and a Mar17 TP of `370.

Cadila gets US FDA nod to sell generic anti-viral drug

The drugs will be manufactured in Ahmedabad

Zydus acquires gastro therapy ‘Actibile’ from Albert David

Strengthens its presence in the gastroenterology segment Zydus Healthcare, a wholly-owned subsidiary of Cadila Healthcare has entered into a definitive agreement to acquire ‘Actibile’ from Albert David. The brand

9 stocks that remained in news today: Lupin, Excel Industries and more

Zydus Healthcare, a subsidiary of Cadila Healthcare, has acquired gastrointestinal brand 'Actibile' from drug firm Albert David for an undisclosed amount.

BSE sensex, nse nifty, gna axles ipo

Cadila Q3 net up 38 per cent at Rs 390 cr

Total income of the company rose to Rs 2,428 crore for the third quarter

FIPB clears 5 FDI proposals worth Rs 6,050 cr; Cadila Healthcare gets nod

Government today approved five foreign investment proposals involving an inflow of Rs 6,050 crore including a Rs 5,000-crore plan of Cadila Healthcare for fresh equity infusion.

USFDA alleges Cadila’s 2 plants for violating CGMP regulations

Torn notebook with record of 'deficiencies', plastic bags filled with shreds of paperwork, failure to adequately investigate and address consumer complaints, are some of the major norm violations found by the USFDA at Cadila

Cadila Healthcare

Cadila Healthcare receives warning letter from US FDA

The letters were received for its two facilities in Gujarat Cadila Healthcare has received a warning letter from the US Food and Drug Administration (US FDA) for its two facilities in Gujarat. “The company has received

Top 8 stocks that made news today: Cadila Healthcare, Petronet LNG and more

Gas importer Petronet LNG will buy liquefied natural gas (LNG) from Qatar's Rasgas at virtually half the original cost, the government said in a statement on Thursday.

bse sensex, nse nifty, stocks to bet on

Cadila Healthcare Ltd shares surge nearly 3% as Q2 net profit zooms 40%

Cadila Healthcare Ltd shares surged on Friday after the company posted 40.56 per cent jump in consolidated net profit to Rs 390.91 for the second quarter ended on September 30, 2015-16.

Aurobindo Pharma

Cadila Healthcare posts 40% jump in net profit to Rs 391 cr

Pharma firm Cadila Healthcare Ltd posted 40.56 per cent jump in consolidated net profit to Rs 390.91 for the second quarter ended on September 30, 2015-16.

Cadila beats estimates, US market the key: Nomura

Cadila Healthcare’s (CDH) Q4 results were above our expectations. Revenue recorded a 16% growth...

Focus on innovation: New drugs top Cadila Healthcare’s prescription for growth

In the pipeline are three novel biologics, 10 vaccines, and two new chemical entities set to complete phase 1 clinical trials by end of 2015.

Biosimilars should contribute 10% to our revenue in 5 years

Cadila's new chemical entity (NCE) pipeline includes two new drugs being developed to treat diabetes and anaemia.

Cadila buys JV partner’s 50 per cent stake in Zydus BSV Pharma

Zydus BSV has now become 100 per cent subsidiary of Cadila Healthcare

Buy Cadila Health, target of Rs 1,763: Nomura

Reiterate buy on Cadila Healthcare with a revised target price of Rs 1,763 from Rs 1,218 earlier.

Torrent Group, Cadila Healthcare among top political donors from Gujarat; BJP ‘only defaulter’

Corporate houses like Torrent Group and Cadila Healthcare Ltd were among the top donors from Gujarat...


Cadila Healthcare Q2 Net up 52% at Rs 278 crore

Cadila Healthcare today reported 51.65 per cent rise in its consolidated net profit...

Income Tax Calculator, Budget 2019, How to Calculate Income Tax

US Stock Market

View All


Stock Market

Most Read


Top News


Related Articles